Eli Lilly and Company

For the trailing twelve months, Eli Lilly generated $29.80 in earnings per share, a 94.6% increase from the prior year. Revenue for the same period rose 49.6%. That means earnings growth outpaced revenue growth by 45 percentage points. The net margin was 33.5%, meaning the company keeps roughly one-third of every revenue dollar as profit. The stock's price-to-earnings ratio stands at 43.17. Based on the earnings growth of 94.6%, the PEG ratio is roughly 0.46. The 52-week trading range is $712.05 to $1292.65, an approximate 82% spread from low to high. The Alpha Score of 55.3 is composed of a quality score of 87 and a value score of 60.5, with momentum and sentiment scores absent. The earnings per share figure is a trailing measure, not a forward estimate. The key metric to watch in the next earnings report is whether revenue growth can stay above 40%. That report will also update margin and earnings figures.

Eli Lilly shares sit near the upper end of their 52-week range, with the stock closing at $1,292.65, just off the high. The company's P/E of 43.17 looks steep, but trailing twelve-month EPS growth of 94.6% and revenue growth of 49.6% have kept the multiple in check. Net margin widened to 33.5%, reflecting strong demand for its diabetes and obesity treatments. The Alpha Score of 55.3 is held back by neutral momentum and sentiment readings, while quality scores 87 and value 60.5. With the stock near its peak, the next catalyst is the upcoming quarterly earnings report, due in early August, which will show whether growth can sustain this pace. Watch for any updates on manufacturing capacity for its GLP-1 drugs, a key constraint on sales.

Eli Lilly shares continue to trade near the top of their 52-week range, supported by a 94.6% surge in EPS and 49.6% revenue growth over the past year. The net margin of 33.5% underscores operating leverage from its obesity and diabetes portfolio. At a P/E of 43.17, the stock commands a premium that the earnings trajectory has largely justified. The Alpha Score of 60.3 is weighted heavily by quality (87) and value (60.5), while momentum registers null and sentiment sits at 50, suggesting the market is pricing in known strengths without fresh catalysts. With the 52-week high at $1,292.65, each new product readout or regulatory decision could tilt the balance. Next quarter's results will test whether margin expansion can keep pace with revenue growth, especially as competition in the GLP-1 space intensifies.

Eli Lilly (LLY) closed with the stock still deep in its 52-week range, roughly 45% off the $1,292.65 high set earlier in the cycle. The numbers that matter keep compounding: revenue grew 49.6% year over year, EPS jumped 94.6%, and net margin sits at 33.5%. That margin profile is the standout, a level most large-cap pharma peers would struggle to match. The P/E of 43.17 looks rich against the S&P 500, though the growth rate softens the optics. Quality is the pillar doing the heavy lifting in the Alpha Score of 60.3, with quality at 87 and value at 60.5; momentum is neutral and sentiment is middling. The bull case rests on the GLP-1 franchise holding share as supply catches up with demand. The bear case is simply the multiple: a miss on any quarterly script number would reset the narrative fast. Watch next week's read on weekly prescription trends, the fastest signal on whether the ramp is still accelerating.

Eli Lilly shares remain elevated near the top of a $712–$1,292 range, supported by a 49.6% revenue jump and a 94.6% EPS surge from the prior year. The net margin of 33.5% underscores the profitability of its GLP-1 franchise. The Alpha Score of 60.1 is driven by a quality sub-score of 87, while momentum at 44.2 and value at 60.5 sit in middle ground. The P/E of 43.17 reflects the premium the market assigns to the growth trajectory. Watch for the next quarterly update, due in early August, for any signal on tirzepatide demand trends and manufacturing capacity.